AQST Latest Headlines

FDA Review for Anaphylm Remains Ongoing: Aquestive Pursues Global Regulatory Approvals Amid Unresolved Application Issues

Market Chameleon (Fri, 9-Jan 7:51 AM)

Aquestive Faces FDA Deficiencies on Anaphylm NDA Review

at www.tipranks.com (Fri, 9-Jan 7:48 AM)

Aquestive drops as FDA flags issues in Anaphylm marketing application

at seekingalpha.com (Fri, 9-Jan 7:43 AM)

Needle-Free Anaphylaxis Treatments Poised for Growth: Physician Survey Supports Buy Rating on Aquestive’s Anaphylm (AQST)

at www.tipranks.com (Thu, 8-Jan 11:25 AM)

Aquestive Therapeutics Expands Leadership Team to Accelerate Anaphylm Launch and Pipeline Growth

Market Chameleon (Tue, 4-Nov 8:35 AM)

Aquestive’s New Patents Extend Anaphylm Protection to 2037—Could This Disrupt Epinephrine Delivery?

Market Chameleon (Thu, 9-Oct 11:59 AM)